GE HealthCare（股票代码：GEHC）宣布，其创新产品Allia Moveo介入造影系统已正式获得美国食品药品监督管理局（FDA）的510(k)许可，并同步取得欧盟CE认证。该系统已完成全球首台装机，标志着其在介入手术室的精准护理应用迈出关键一步。
此次双认证的通过，彰显了Allia Moveo系统在技术性能、安全性和有效性方面符合国际高标准。该系统的部署将助力临床医生在复杂的血管介入、肿瘤介入等手术中实现更精准的导航与操作，从而提升手术成功率与患者预后。
作为GE Healthcare在精准医疗领域的重要布局，Allia Moveo的全球首台安装不仅体现了公司在介入影像解决方案上的技术领先性，也为后续市场推广奠定了坚实基础。该进展有望进一步巩固GE Healthcare在高端医疗设备领域的竞争优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.